GSK - GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial Cancer | Benzinga

Saturday, GSK plc (NYSE:GSK) announced overall survival (OS) results from Part 1 and progression-free survival (PFS) results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial of Jemperli (dostarlimab) for primary advanced or recurrent endometrial cancer, paving the way for a potential label expansion beyond its current indication.

In 2023, the FDA approved Jemperli in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or Full story available on Benzinga.com